Summary statistics - quantitative results

(Groups: manufacturer of instrument)

Filter: minimal size of groups n = 5

EQA round: AP2/19 - Antithrombotic Agents

Dead line: 13.09.2019

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U_{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	RoM	SD	CV [%]	N_{tot}	N_{out}	Comparability	AV	U_{AV}	D_{max}	LL	UL	N_{eva}	N_{suc}	S_{rel}
Set 1															
(108) Apixaban	[µg/L]				27								27	26	96%
Samples and groups															
Sample A1		205	15	7,4	27		CVP	205	7,1	25%	153	257	27	26	96%
(38) IL		211	6,5	3,1	7	0							7		
(63) Sysmex		198	18	9,0	9	0							9		
(94) Stago		208	7,4	3,6	7	0							7		
Other					4	0	3x 149, 1x 179						4		
Sample B1		421	24	5,6	27		CVP	421	11	25%	315	527	27	27	100%
(38) IL		428	15	3,5	7	0							7		
(63) Sysmex		420	29	6,9	9	0							9		
(94) Stago		427	33	7,8	7	0							7		
Other					4	0	3x 149, 1x 179						4		
Set 2															
(109) Dabigatran	[µg/L]				33								33	33	100%
Samples and groups															
Sample A2		100	12	12	33		CVP	100	5,1	25%	75	125	33	33	100%
(38) IL		97,5	3,7	3,8	9	0							9		
(63) Sysmex		103	12	11	14	0							14		
(94) Stago		103	16	16	6	0							6		
Other					4	0	3x 149, 1x 179						4		
Sample B2		304	33	11	33		CVP	304	14	25%	228	380	33	33	100%
(38) IL		295	44	15	9	0							9		
(63) Sysmex		312	18	5,9	14	0							14		
(94) Stago		300	21	6,9	6	0							6		
Other					4	0	3x 149, 1x 179						4		
Set 3															
(110) Rivaroxaban	[µg/L]				35								35	33	94%
Samples and groups															
Sample A3		98,8	12	12	35		CVP	98,8	5,0	25%	74,1	124	35	33	94%
(38) IL		92,9	4,6	4,9	8	0							8		
(63) Sysmex		102	14	13	15	0							15		
(94) Stago		90,2	6,2	6,9	7	0							7		
Other					5	0	4x 149, 1x 179						5		
Sample B3		309	31	9,9	35		CVP	309	13	25%	231	387	35	34	97%
(38) IL		269	15	5,6	8	0							8		
(63) Sysmex		329	14	4,1	15	0							15		
(94) Stago		305	24	8,0	7	0							7		
Other					5	0	4x 149, 1x 179						5		